What are the recommended dosing and titration guidelines for disease-modifying antirheumatic drugs (DMARDs) such as methotrexate, other conventional synthetic DMARDs, biologic DMARDs, and targeted synthetic DMARDs?

DMARD Dosage and Titration

For DMARD-naive rheumatoid arthritis patients, initiate methotrexate at 15 mg weekly (or at least 10 mg/week), titrate to at least 15 mg within 4-6 weeks, and start with oral administration; if disease activity persists after 3-6 months despite optimization, add a biologic or targeted synthetic DMARD rather than switching methotrexate. 1

Methotrexate: First-Line Therapy

Initial Dosing and Route

• Start oral methotrexate at ≥15 mg weekly, reaching this dose within 4-6 weeks 1
• Oral route is preferred initially due to ease of administration and similar bioavailability at typical starting doses 1
• The FDA label supports starting doses of 10-25 mg/week for rheumatoid arthritis 2
• Doses >20 mg/week in adults significantly increase risk of serious toxicity, particularly bone marrow suppression 2

Titration Strategy

The 2021 ACR guideline provides clear direction: titrate to at least 15 mg weekly within 4-6 weeks 1. This recommendation acknowledges the tradeoff between increased efficacy and toxicity at higher starting doses. Further dose escalation beyond 15 mg often provides additional efficacy and should not be limited by this initial recommendation 1.

Optimizing Methotrexate Before Switching

If patients don't reach target on oral methotrexate:

1. Switch to subcutaneous administration - conditionally recommended over adding/switching to alternative DMARDs 1
2. Consider split dosing over 24 hours for intolerance 1
3. Increase folic/folinic acid supplementation (minimum 5 mg folic acid weekly, separated from methotrexate dose) 3

The guideline emphasizes maximizing methotrexate use before advancing therapy, as subcutaneous administration may overcome oral absorption limitations 1.

Disease Activity-Based Treatment Algorithms

Low Disease Activity (DMARD-Naive)

The treatment hierarchy differs for low disease activity:

• Hydroxychloroquine > other csDMARDs (better tolerated, favorable risk profile) 1
• Sulfasalazine > methotrexate (less immunosuppressive) 1
• Methotrexate > leflunomide (greater dosing flexibility, lower cost) 1

Moderate-to-High Disease Activity

Timeline for escalation: If no improvement by 3 months or target not reached by 6 months, adjust therapy 4

For DMARD-naive patients:

• Methotrexate should be part of first treatment strategy 4
• If contraindication to methotrexate exists, use leflunomide or sulfasalazine 4

After csDMARD failure with poor prognostic factors (autoantibodies, high disease activity, early erosions):

• Add a bDMARD or tsDMARD to methotrexate rather than switching 1, 4
• bDMARDs and tsDMARDs should be combined with a csDMARD 4
• IL-6 pathway inhibitors and tsDMARDs may have advantages when csDMARDs cannot be used as comedication 4

Biologic and Targeted Synthetic DMARD Dosing

After First b/tsDMARD Failure

No change in methotrexate dosage is recommended when adding a TNF antagonist 3. The STRATEGE2 study found that 97.7% of patients continued methotrexate at b/tsDMARD initiation, with 39.9% maintaining the same dosage and route at 12 months 5.

When a bDMARD or tsDMARD fails, switch to another bDMARD or tsDMARD (different or same class) 4. After TNF inhibitor failure, either another TNF inhibitor or an agent with different mechanism of action is appropriate 4.

Comparative Efficacy After b/tsDMARD Failure

High-certainty evidence supports these interventions over placebo (ACR50 response) 6:

• Tocilizumab 8 mg/kg IV: OR 10.03 (most effective)
• Rituximab: OR 5.50
• TNF inhibitor not previously tried: OR 6.04
• Tocilizumab 4 mg/kg IV: OR 5.31
• Abatacept IV: OR 4.57
• Subcutaneous abatacept: OR 4.31
• JAK inhibitors (upadacitinib, tofacitinib): OR 3.93
• Sarilumab: OR 3.11
• Baricitinib 4 mg: OR 2.79

Glucocorticoid Co-Administration

Short-term glucocorticoids should be considered when initiating or changing csDMARDs, but tapered as rapidly as clinically feasible 4. The 2021 ACR guideline strongly recommends against longer-term (≥3 months) glucocorticoid use due to significant toxicity outweighing benefits 1.

Tapering in Remission

bDMARD/tsDMARD Tapering

If persistent remission is achieved after tapering glucocorticoids, consider tapering bDMARDs or tsDMARDs, especially if combined with a csDMARD 4. Level of agreement: 9.2/10 4.

csDMARD Tapering

If persistent remission continues, tapering the csDMARD could be considered 4. However, when methotrexate is discontinued, arthritis usually worsens within 3-6 weeks 2.

Critical Monitoring Requirements

Pre-Treatment Assessment (Mandatory) 3:

• Complete blood count
• Serum transaminases
• Serum creatinine with creatinine clearance calculation
• Chest radiograph
• Hepatitis B and C serologies (recommended)
• Serum albumin (recommended)
• Pulmonary function tests with DLCO if respiratory history/symptoms present

Ongoing Monitoring 3:

• CBC, transaminases, creatinine: monthly for first 3 months, then every 4-12 weeks

Common Pitfalls

1. Starting methotrexate too low (<10 mg/week) - delays achieving therapeutic effect 1
2. Switching away from methotrexate prematurely - optimize route and dosing first 1
3. Continuing inadequate therapy beyond 6 months - violates treat-to-target principles 4
4. Using longer-term glucocorticoids (≥3 months) - toxicity outweighs benefits 1
5. Stopping methotrexate when adding bDMARD/tsDMARD - combination therapy is superior 4